A randomized phase II study of palbociclib plus exemestane with GNRH agonist versus capecitabine in premenopausal women with hormone receptor-positive metastatic breast cancer (KCSG-BR 15-10, NCT02592746).

Category Primary study
JournalJOURNAL OF CLINICAL ONCOLOGY
Year 2019
This article has no abstract
Epistemonikos ID: da705bc6711e3be407260fc64b303fe32049431a
First added on: Feb 11, 2025